课题基金 / 基金详情

Hyperbaric Oxygenation May Increase Lung Injury

Hyperbaric Oxygenation May Increase Lung Injury
高压氧可能会增加肺损伤
批准号:
7034016
负责人:
Michail Sitkovsky
金额:
$19.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2008-04-30

项目摘要

项目成果

Michail Sitkovsky的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hyperbaric Oxygen therapy (HBOT) is of interest to basic biomedical researchers and to practitioners of complementary and alternative medicine (CAM). HBOT is applied to a wide variety of diseases with symptoms caused by a lack of oxygen in the target tissues. It is not accepted as a treatment by the US medical community due to the lack of understanding of the underlying physiology and yet to be carefully evaluated potential dangers. Extensive pre-clinical studies are required to overcome the current bias towards HBOT and to determine its limitations. The central goal of this proposal is to understand the mechanisms of beneficial effects of HBOT and to identify its potential dangers. We recently established the critical role of the hypoxia-driven and A2A and A2B adenosine receptor (A2AR/A2BR)-mediated pathway in inhibition of overactive inflammatory cells and protection of normal tissues in hypoxic inflamed areas. We hypothesize that the elimination of this mechanism by oxygen during HBOT may explain the beneficial effects of HBOT in clearing infections by "de-inhibited" immunocytes. We are also concerned that the weakening of this protective mechanism by HBOT may lead to an unintended exacerbation of inflammatory tissue damage. We plan to test our hypothesis in studies of HBOT-treated wild type mice and of unique mice with total and tissue-specific deletion of A2AR and/or A2BR genes in different models of lung inflammation. Our specific aims #1 and 2 are to test whether HBOT exacerbates lung inflammation in studies of inhalative and intravenously induced models of lung injury in mice, while in Aim #3 we will test whether compensatory treatment with A2AR agonist will prevent the inflammatory lung injury exacerbation by HBOT in order to gain potential benefits of HBOT for other indications in CAM and other therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
  • 批准号:
    8043237
  • 项目类别:
  • 资助金额:
    $28.45万
  • 财政年份:
    2010
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7100600
  • 项目类别:
  • 资助金额:
    $22.29万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7409103
  • 项目类别:
  • 资助金额:
    $21.65万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
  • 批准号:
    8464014
  • 项目类别:
  • 资助金额:
    $20.15万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
国内基金
海外基金
缺氧诱导因子(HIF)-2α转录抑制树突状细胞CD36表达减轻肾脏缺血再灌注损伤的机制
  • 批准号:
    82370751
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    张明
  • 依托单位:
靶向纳米颗粒调控HIF-1α通路抑制缺氧三阴性乳腺癌耐药和转移的研究
  • 批准号:
    31900567
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    田浩
  • 依托单位:
Egr-1调控低氧下细胞自噬引起肝癌化疗抵抗的机制研究
  • 批准号:
    31100964
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2011
  • 负责人:
    彭琬昕
  • 依托单位:
肝刺激因子HSS对肝脏缺血-再灌注损伤的保护作用及机制
  • 批准号:
    81100310
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2011
  • 负责人:
    李文
  • 依托单位: